ATF5 and cancer: Karpel-Massler et al. evaluated the effect of a synthetic cell-penetrant variant of dnATF5 (CP-d/n-ATF5-S1) on the growth of a diverse panel of treatment resistant cancers, including the PANC-1 pancreatic carcinoma cell line [56].